Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578880 | 0.96 | KDM2B (0.42) | OPRM1OPRK1OPRL1KDM2BAXL | |
| SCHEMBL5578621 | 0.87 | OPRM1 (0.43) | OPRM1OPRK1OPRL1AXLMERTK | |
| SCHEMBL5579103 | 0.85 | HDAC1 (0.48) | OPRL1KDM2BCYP2D6SIGMAR1 | |
| SCHEMBL5579955 | 0.84 | KDM2B (0.43) | OPRM1OPRK1OPRL1KDM2BAXL | |
| SCHEMBL5578452 | 0.84 | KDM2B (0.45) | OPRM1OPRK1OPRL1KDM2BHSD11B1 | |
| SCHEMBL5578618 | 0.83 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL5578766 | 0.83 | HDAC1 (0.38) | HSD11B1SIGMAR1 | |
| SCHEMBL5578801 | 0.83 | OPRM1 (0.42) | OPRM1OPRK1OPRL1AXLMERTK | |
| SCHEMBL5578869 | 0.83 | OPRM1 (0.43) | OPRM1OPRK1OPRL1AXLMERTK | |
| SCHEMBL5578896 | 0.83 | OPRM1 (0.45) | OPRM1OPRK1OPRL1AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | OPRM1 630/4885OPRK1 131/4885OPRL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.